Skip to main content
main-content

Rheumatology

Latest articles

24-04-2018 | Rheumatology | News | Article

Pain, comorbidity burden high in patients with spondyloarthritis

Results of two studies emphasize the important of taking pain and comorbidities into account when treating patients with spondyloarthritis.

Source:

BMC Rheumatology 2018; 2: 11
Clin Rheumatol 2018; Advance online publication

23-04-2018 | Rheumatology | News | Article

Verinurad–febuxostat combination shows promise for the treatment of gout

Results of a phase IIa trial support further investigation of the selective URAT1 inhibitor verinurad in combination with febuxostat for the treatment of gout.

Source:

RMD Open 2018; 4: e000647

20-04-2018 | Rheumatology | News | Article

JIA recommendations define treat-to-target strategy

An international taskforce has developed consensus recommendations for treating juvenile idiopathic arthritis to target.

Source:

Ann Rheum Dis 2018; Advance online publication

19-04-2018 | Rheumatology | News | Article

‘Reassuring’ data on certolizumab pegol use during pregnancy

Treatment with the tumor necrosis factor inhibitor certolizumab pegol during pregnancy is not likely to be associated with teratogenic effects, researchers report.

Source:

Arthritis Rheumatol 2018; Advance online publication

18-04-2018 | Rheumatology | News | Article

News in brief

Further evidence for sustained benefits of adalimumab in axSpA

Extension results from the ABILITY-1 trial support the long-term benefits of adalimumab for patients with nonradiographic axial spondyloarthritis.

17-04-2018 | Rheumatology | News | Article

High TNF inhibitor retention rate in SpA patients

Researchers have found that the long-term retention rate for a first tumor necrosis factor inhibitor is favorable in patients with spondyloarthritis.

Source:

J Rheumatol 2018; Advance online publication

16-04-2018 | Rheumatology | News | Article

Arthritis disease activity may influence pregnancy outcome

Results of an observational study suggest that pregnant women with rheumatoid arthritis or axial spondyloarthritis have an elevated risk for pregnancy complications, and disease activity may be a risk factor for preterm delivery.

Source:

Rheumatology 2018; Advance online publication

12-04-2018 | Rheumatology | Highlight | Article

Editor's pick

Trial results back denosumab as a treatment option for glucocorticoid-induced osteoporosis

Patients with glucocorticoid-induced osteoporosis who are treated with denosumab have greater improvements in bone mineral density than those treated with risedronate, phase III trial results suggest.

Source:

Lancet Diabetes Endocrinol 2018; Advance online publication

12-04-2018 | Rheumatology | News | Article

PALACE 4 results support apremilast for DMARD-naïve patients with PsA

Phase III trial findings suggest that treatment with the phosphodiesterase 4 inhibitor apremilast is beneficial for patients with psoriatic arthritis who have not received prior treatment with conventional or biologic DMARDs.

Source:

Rheumatology 2018; Advance online publication

11-04-2018 | Rheumatology | News | Article

Obesity associated with worse short-term disease activity in early RA

Among patients with early rheumatoid arthritis, those who are obese are at increased risk for having worse disease activity, function, and health-related quality of life, according to an analysis of data from two UK cohorts.

Source:

Rheumatology 2018; Advance online publication

10-04-2018 | Rheumatology | News | Article

Editor's pick

Recommendations for treating JIA-associated uveitis published

The SHARE initiative has developed consensus evidence-based recommendations for the treatment of uveitis associated with juvenile idiopathic arthritis.

Source:

Ann Rheum Dis 2018; Advance online publication

09-04-2018 | Rheumatology | News | Article

News in brief

Diabetes associated with accelerated cartilage deterioration

Study results from the Osteoarthritis Initiative suggest that diabetes is associated with faster degeneration of knee cartilage among patients with osteoarthritis.

06-04-2018 | Rheumatology | News | Article

News in brief

Unmet clinical needs persist in RA

Results of a European study indicate that a substantial proportion of patients with rheumatoid arthritis have inadequately controlled disease.

04-04-2018 | Rheumatology | News | Article

Editor's pick

Risk factors for methotrexate failure in inflammatory polyarthritis identified

UK researchers have identified characteristics in patients with inflammatory polyarthritis that may make them less likely to respond to oral methotrexate treatment.

Source:

Arthritis Res Ther 2018; 20: 50

03-04-2018 | Rheumatology | News | Article

approvalsWatch

EMA backs infliximab biosimilar

The EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of a new infliximab biosimilar for the treatment of various types of arthritis.

03-04-2018 | Rheumatology | News | Article

Blisibimod SLE trial fails to reach primary endpoint

The phase III CHABLIS-SC1 trial comparing blisibimod with placebo in patients with systemic lupus erythematosus has not reached its primary endpoint of improvement in the SLE responder index at 1 year, researchers report.

Source:

Ann Rheum Dis 2018; Advance online publication

29-03-2018 | Rheumatology | News

RA drugs have limited effect on pneumococcal vaccination efficacy

Researchers report that some antirheumatic drugs may limit the humoral response of patients with rheumatoid arthritis to pneumococcal vaccination, but they nonetheless stress that this should not preclude immunization against such preventable diseases.

Source:

J Rheumatol 2018; advance online publication

29-03-2018 | Rheumatology | News | Article

News in brief

Microbiome may contribute to SLE pathogenesis

Commensal bacteria may be involved in triggering systemic lupus erythematosus in genetically predisposed individuals, results of a proof-of-concept study suggest.

28-03-2018 | Rheumatology | News | Article

News in brief

Long-term RAPID-PsA results point to sustained efficacy of certolizumab pegol

Open-label extension results from the RAPID-PsA trial suggest that the benefits of certolizumab pegol are maintained for up to 4 years among patients with psoriatic arthritis.

28-03-2018 | Rheumatology | News | Article

Disease activity, CRP levels associated with postoperative flare risk in RA patients

Rheumatoid arthritis patients who have higher disease activity and those with elevated levels of C-reactive protein are at increased risk for flare following surgery, researchers report.

Source:

J Rheumatol 2018; Advance online publication

image credits